RSLS
ReShape Lifesciences Inc.
-48.86%
$5.91 - $3.02
Feb 8th 2023 - Mar 22nd 2023
Feb, 16, 2023
$RSLS Nice consolidation phase before this one goes.
Feb, 8, 2023
$RSLS nice green boom boom after closed offering ... See more
BBAI
BigBear.ai Holdings Inc
-61.99%
$4.92 - $1.87
Feb 7th 2023 - Mar 21st 2023
Feb, 9, 2023
At 🌋 phase.
Feb, 3, 2023
$BBAI They have to factor in the jobs report which... See more
SLS
SELLAS Life Sciences Group Inc
-63.99%
$3.61 - $1.30
Feb 7th 2023 - Mar 21st 2023
Mar, 20, 2023
It reported positive outcomes in pleural mesotheli... See more
Mar, 20, 2023
PROC data are excellent compared to any combo trials.
Feb, 16, 2023
$RSLS Nice consolidation phase before this one goes.
Feb, 8, 2023
$RSLS nice green boom boom after closed offering $FWBI new clinical study news $KPRX $CELZ $ICU
Jan, 3, 2023
$PBLA multiple phase 3 trail ..price 8 cents ..dirt cheap $KALA $RSLS $ATNF $PTPI
Feb, 9, 2023
At 🌋 phase.
Feb, 3, 2023
$BBAI They have to factor in the jobs report which was excellent as well, it means that AI isn't going to phase out a key aspect of the economy.
Mar, 20, 2023
It reported positive outcomes in pleural mesothelioma patients, including: Improved survival: Study patients lived around 11 months.
Mar, 20, 2023
PROC data are excellent compared to any combo trials.
Mar, 8, 2023
But yesterdays paper also has me considering, if there isn't a deal with $mrk or $BMY or some other CPI BP --- That data is Best In Class - best in clinic, best in trial too.
Mar, 3, 2023
phase II results within weeks!!!
Feb, 27, 2023
Now phase 3 trial is showing similar results to date where patients are living longer after Galinpepimut-S up to 1.5 year longer is a breakthrough for AML patients.
Feb, 6, 2023
Positive trial data/results supported with bullish news and sentiment! 4.
Jan, 24, 2023
The nation’s best means the O'Neal Comprehensive Center in Alabama have access to the latest therapies, cutting-edge clinical trials and the expertise needed to treat their cancer.
Jan, 24, 2023
Gps is doing what it has done in every single trial and its the reason Patients are living 3 fold longer than patients on best available treatments.
Jan, 11, 2023
Treatment with GFH009 resulted in 90 to 100 percent cancer inhibition at dose levels equivalent to those already demonstrated to be safe in patients in the ongoing Phase 1 trial with no viable cancer cells at the highest dose levels.